Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial

Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus

(2017) Wenjie Dai et al.   MEDICINE

Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes

(2016) Tim Heise et al.   CLINICAL THERAPEUTICS

3. Comprehensive Medical Evaluation and Assessment of Comorbidities

(2016)   DIABETES CARE

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin

(2016) Matthias Kern et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

(2016) Teruo Jojima et al.   Diabetology & Metabolic Syndrome

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus

(2015) Ian J Neeland et al.   Diabetes & Vascular Disease Research

Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences

(2015) Linda A Gallo et al.   Diabetes & Vascular Disease Research

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial

(2015) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

(2014) Hans-Ulrich Häring et al.   DIABETES CARE

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

(2014) Julio Rosenstock et al.   DIABETES CARE

Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome

(2014) G. Forlani et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes

(2014) Rachel J. Perry et al.   NATURE

Non-alcoholic fatty liver disease

(2014) N. Sattar et al.   BMJ-British Medical Journal

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

(2014) Martin Ridderstråle et al.   Lancet Diabetes & Endocrinology

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

(2013) H.-U. Haring et al.   DIABETES CARE

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

(2013) C. S. Kovacs et al.   DIABETES OBESITY & METABOLISM

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

(2013) Michael Roden et al.   Lancet Diabetes & Endocrinology

Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study

(2011) R. M. Williamson et al.   DIABETES CARE

Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus

(2010) Nathalie C. Leite et al.   LIVER INTERNATIONAL

Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause

(2008) R. Taylor   DIABETOLOGIA